Get started
Author

Mark E Sellers

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
2011 · C. Kent Osborne, Patrick Neven, et al. · Clinical Cancer Research · 179
PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
2007 · Jean-Yves Douillard, Edward Kim, et al. · Journal of Thoracic Oncology · 86
PDF
The SEER Program’s longstanding commitment to making cancer resources available
2024 · Patricia K Murphy, Mark E Sellers, et al. · JNCI Monographs · 16
PDF
2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)
2007 · J.Y. Douillard, E.S. Kim, et al. · European Journal of Cancer Supplements · 14
Reply to D. Tassinari et al
2009 · Yukito Ichinose, Masahiro Fukuoka, et al. · Journal of Clinical Oncology · 1
Stat Bite: Cancer risk factors in the US in 2024; obesity, BMI ≥ 30 in people over 20 years
2026 · Mark E Sellers, Kathleen A Cronin · JNCI Journal of the National Cancer Institute
Stat Bite: A reversal of esophageal cancer mortality between non-Hispanic Black and White individuals in the United States
2026 · Hyuna Sung, Chenxi Jiang, et al. · JNCI Journal of the National Cancer Institute
Stat Bite: Recent trends in ovarian cancer among Non-Hispanic Black and Non-Hispanic White women
2025 · Mark E Sherman, Mark E Sellers, et al. · JNCI Journal of the National Cancer Institute
PDF
Works count: 8
Citation count: 296
H-index: 4
I10-index: 4
Year
Topic
Type